December 02, 2009
Kalbitor approved for acute attacks of hereditary angioedema (HAE)
Kalbitor-treated patients demonstrated a greater decrease from baseline in the mean MSCS than placebo (-0.8 vs. -0.4) and a greater mean TOS (53 vs. 8) in the EDEMA4 trial at 4 hours. In the EDEMA4 trial at 24 hours, Kalbitor treatment also resulted in a greater decrease from baseline in the mean MSCS than placebo (-1.5 vs. -1.1) and a greater mean TOS (89 vs. 55). The results in the EDEMA3 trial were consistent with that of EDEMA4.
Kalbitor will be made available in 10mg/mL single-use vials.
For more information call (888) 4KALBITOR or visit www.kalbitor.com.